An Exploratory Safety and Efficacy Clinical Study of CARDIX-101 for the Treatment of Chronic Bradycardia
Latest Information Update: 22 Jul 2022
At a glance
- Drugs CARDIX-101 (Primary)
- Indications Bradycardia
- Focus Adverse reactions; Therapeutic Use
- Sponsors CARDIX Therapeutics
- 18 Jul 2022 Planned End Date changed from 20 Dec 2023 to 20 Dec 2024.
- 18 Jul 2022 Planned primary completion date changed from 20 Dec 2023 to 20 Dec 2024.
- 18 Jul 2022 Planned initiation date changed from 6 May 2022 to 1 Aug 2022.